Moncef Slaoui, GlaxoSmithKline

2013 pay package: $8.4 million
2012 pay package: $6.6 million
Change: +27%
2013 compensation: $1.9 million in salary and benefits; $2 million bonus; $4.3 million in long-term incentive stock awards; $266,000 in pension

A roughly 250% increase in long-term incentive stock awards helped GlaxoSmithKline R&D boss Moncef Slaoui jump quite a few spots among his highest-paid peers, and the U.K. drugmaker's ($GSK) big bet on its head scientist comes amid a transformational time for the company's research arm.

GSK turned in something of a mixed bag on the R&D front last year. Thanks to its years-long partnership with Theravance ($THRX), the company scored two major approvals for COPD treatments--including for the likely blockbuster Anoro Ellipta--and, on its own, picked up an FDA nod for the GLP-1 diabetes drug albiglutide, marketed as Tanzeum. But the pharma stalwart endured discouraging late-stage setbacks to darapladib, a once-promising cardio therapy; MAGE-A3, a long-in-development cancer vaccine; and drisapersen, an innovative treatment for Duchenne muscular dystrophy developed alongside Prosensa ($RNA).

Now, in keeping with the industrywide trend of sticking to what you know, GSK sees better living through simplicity. In April, the drugmaker signed a deal to essentially hand over its oncology division en masse to Novartis ($NVS) for up to $16 billion, getting back the Swiss company's vaccines unit and in the process doubling down on the spaces in which it has found success: respiratory, HIV, vaccines and consumer healthcare.

Once that deal closes, GSK will retain much of its early-phase cancer pipeline, but the company's late-stage fate will largely hinge on whether Slaoui and his team can deliver on next-gen respiratory drugs like mepolizumab and losmapimod; reclamation projects like darapladib's program in diabetic macular edema; and the Johnson & Johnson-partnered arthritis contender sirukumab.

- here's the annual report (PDF)

For more:
Special Report: The top R&D spenders in biopharma in 2013 - GlaxoSmithKline: A big swap simplifies things
GlaxoSmithKline's blockbuster dreams dashed as darapladib goes 0-for-2 in PhIII
GlaxoSmithKline R&D chief touts the future of 'electroceuticals'
GlaxoSmithKline reloads its pipeline with new PhIII drugs following approvals, setbacks

Moncef Slaoui, GlaxoSmithKline
Read more on

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.